Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors

gan Haznedaroğlu, İbrahim C.
Cyhoeddwyd 2013

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)

gan Haznedaroglu, Ibrahim C.
Cyhoeddwyd 2014

Drug Therapy in the Progressed CML Patient with multi-TKI Failure

gan Haznedaroglu, Ibrahim C.
Cyhoeddwyd yn Mediterr J Hematol Infect Dis (2015)

Immunogenomic phases of COVID-19 and appropriate clinical management

gan Haznedaroglu, Ibrahim C
Cyhoeddwyd yn Lancet Microbe (2020)

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

gan Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Cyhoeddwyd yn Turk J Haematol (2018)

COVID-19, Renin-Angiotensin System, and Hematopoiesis

gan Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Cyhoeddwyd yn Turk J Haematol (2020)

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia

gan Malkan, Umit Y., Haznedaroglu, Ibrahim C.
Cyhoeddwyd yn Open Med (Wars) (2018)

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

gan Koluman, Ahmet, Akar, Nejat, Haznedaroğlu, İbrahim C.
Cyhoeddwyd yn Turk J Haematol (2017)

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

gan Okay, Müfide, Çetik, Sıla, Haznedaroğlu, İbrahim C.
Cyhoeddwyd yn Turk J Haematol (2019)

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

gan Okay, Mufide, Ozturk, Yusuf, Haznedaroglu, Ibrahim C.
Cyhoeddwyd yn Clin Appl Thromb Hemost (2019)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

gan Haznedaroğlu, İbrahim C., Kuzu, Işınsu, İlhan, Osman
Cyhoeddwyd yn Turk J Haematol (2020)

A New Candidate as a Hemostatic Agent for Difficult Situations During Variceal Bleeding: Ankaferd Blood Stopper

gan Ozaslan, Ersan, Purnak, Tugrul, Yildiz, Ayla, Haznedaroglu, Ibrahim C.
Cyhoeddwyd 2011

Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach

gan Koçak, Engin, Çelebier, Mustafa, Haznedaroglu, Ibrahim C., Altınöz, Sacide
Cyhoeddwyd yn Biomed Res Int (2019)

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

gan Beyazit, Fatma, Beyazit, Yavuz, Tanoglu, Alpaslan, Haznedaroglu, Ibrahim C.
Cyhoeddwyd yn Med Hypotheses (2020)

Local Bone Marrow Renin-Angiotensin System and Atherosclerosis

gan Beyazit, Yavuz, Purnak, Tugrul, Guven, Gulay Sain, Haznedaroglu, Ibrahim C.
Cyhoeddwyd 2010

Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids

gan Koluman, Ahmet, Akar, Nejat, Malkan, Umit Y., Haznedaroglu, Ibrahim C.
Cyhoeddwyd yn Biomed Res Int (2016)

Ankaferd hemostat in the management of gastrointestinal hemorrhages

gan Beyazit, Yavuz, Kekilli, Murat, Haznedaroglu, Ibrahim C, Kayacetin, Ertugrul, Basaranoglu, Metin
Cyhoeddwyd 2011

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

gan Ciftciler, Rafiye, Ciftciler, Ali Erdinc, Malkan, Umit Yavuz, Haznedaroglu, Ibrahim C
Cyhoeddwyd yn SAGE Open Med (2020)

In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coron...

gan Turk, Can, Turk, Seyhan, Temirci, Elif Sena, Malkan, Umit Yavuz, Haznedaroglu, İbrahim C.
Cyhoeddwyd yn J Renin Angiotensin Aldosterone Syst (2020)

In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases

gan Kocabeyoglu, Sibel, Mocan, Mehmet C, Haznedaroglu, Ibrahim C, Uner, Aysegul, Uzunosmanoglu, Enes, Irkec, Murat
Cyhoeddwyd yn Indian J Ophthalmol (2014)